Based on the provided sources, there is no information specifically about alternative treatments to lurbinectedin for premature infants. However, it is important to note that lurbinectedin is not indicated for use in premature infants.

Lurbinectedin is a medication that is primarily used in the treatment of certain types of cancer, specifically small cell lung cancer. It works by inhibiting the growth of cancer cells [1]. The sources provided do not mention any alternative treatments for premature infants.

The FDA document [2] provides information about the approval of lurbinectedin for the treatment of certain types of cancer, but it does not mention its use in premature infants or alternative treatments for this population.

The Medscape reference [3] provides information about metronidazole (Flagyl), which is a different medication used for various infections. However, it does not mention any alternative treatments to lurbinectedin for premature infants.

In conclusion, based on the provided sources, there is no information available regarding alternative treatments to lurbinectedin specifically for premature infants. It is important to consult with a healthcare professional for appropriate treatment options for premature infants.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] U.S. Food and Drug Administration. Lurbinectedin Approval Letter. Retrieved from https://www.fda.gov/media/105933/download
[3] Medscape. Metronidazole (Flagyl). Retrieved from https://reference.medscape.com/drug/flagyl-metronidazole-342566